Ligand Pharma (LGND) Tops Q2 EPS by 10c; Affirms FY16 Outlook

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.12 million.

The Company affirms expectations for full-year 2016 total revenues to be between $115 million and $119 million, and adjusted earnings per diluted share to be between $3.41 and $3.46. Second half total revenues are projected to be in the range of $66 million to $70 million, and adjusted earnings per share are projected to be in the range of $1.94 to $1.99.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• S&P Global releases recast financials after Mobility spin-off
• Cloudastructure restructures preferred stock, issues $1.3M promissory note